J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Solid Biosciences yesterday and set a price target of $11.00. The company’s shares closed yesterday at $6.62.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence

Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Erasca, and Zai Lab. According to TipRanks, Rama has an average return of 21.9% and a 50.20% success rate on recommended stocks.

Solid Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $17.22, which is a 160.12% upside from current levels. In a report released on May 18, Wedbush also maintained a Buy rating on the stock with a $16.00 price target.

Based on Solid Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $56.74 million. In comparison, last year the company had a GAAP net loss of $39.28 million